BACKGROUND: Cohort studies have reported a high prevalence of musculoskeletal, neurologic, auditory, and visual complications among Ebola virus disease (EVD) survivors. However, little is known about the host- and disease-related predictors of these symptoms and their etiological mechanisms. METHODS: The presence and patterns of 8 cardinal symptoms that are most commonly reported following EVD survival were assessed in the 326 EVD survivors who participated in the ongoing longitudinal Liberian EVD Survivor Study. At quarterly study visits, symptoms that developed since acute EVD were recorded and blood was collected for biomarkers of inflammation and immune activation. RESULTS: At baseline (mean 408 days from acute EVD), 75.5% of survivors reported at least 1 new cardinal symptom since surviving EVD, which in 85.8% was rated as highly interfering with life. Two or more incident symptoms were reported by 61.0% of survivors, with pairings of joint pain, headache, or fatigue the most frequent. Women were significantly more likely than men to report headache, while older age was significantly associated with musculoskeletal and visual symptoms. In analyses adjusted for multiple comparisons, no statistically significant association was found between any symptom and 26 markers of inflammation and immune activation. Symptom frequency remained largely unchanged during study follow-up. CONCLUSIONS: Post-EVD complications occur in a majority of survivors and remain present more than 4 years after acute infection. An association between markers of inflammation and immune activation and individual symptoms was not found, suggesting an alternative etiology for persistent post-EVD symptomatology.
BACKGROUND: Cohort studies have reported a high prevalence of musculoskeletal, neurologic, auditory, and visual complications among Ebola virus disease (EVD) survivors. However, little is known about the host- and disease-related predictors of these symptoms and their etiological mechanisms. METHODS: The presence and patterns of 8 cardinal symptoms that are most commonly reported following EVD survival were assessed in the 326 EVD survivors who participated in the ongoing longitudinal Liberian EVD Survivor Study. At quarterly study visits, symptoms that developed since acute EVD were recorded and blood was collected for biomarkers of inflammation and immune activation. RESULTS: At baseline (mean 408 days from acute EVD), 75.5% of survivors reported at least 1 new cardinal symptom since surviving EVD, which in 85.8% was rated as highly interfering with life. Two or more incident symptoms were reported by 61.0% of survivors, with pairings of joint pain, headache, or fatigue the most frequent. Women were significantly more likely than men to report headache, while older age was significantly associated with musculoskeletal and visual symptoms. In analyses adjusted for multiple comparisons, no statistically significant association was found between any symptom and 26 markers of inflammation and immune activation. Symptom frequency remained largely unchanged during study follow-up. CONCLUSIONS: Post-EVD complications occur in a majority of survivors and remain present more than 4 years after acute infection. An association between markers of inflammation and immune activation and individual symptoms was not found, suggesting an alternative etiology for persistent post-EVD symptomatology.
Authors: Michael C Sneller; Cavan Reilly; Moses Badio; Rachel J Bishop; Allen O Eghrari; Soka J Moses; Kumblytee L Johnson; Dehkontee Gayedyu-Dennis; Lisa E Hensley; Elizabeth S Higgs; Avindra Nath; Kaylie Tuznik; Justin Varughese; Kenneth S Jensen; Bonnie Dighero-Kemp; James D Neaton; H Clifford Lane; Mosoka P Fallah Journal: N Engl J Med Date: 2019-03-07 Impact factor: 91.245
Authors: Jay B Varkey; Jessica G Shantha; Ian Crozier; Colleen S Kraft; G Marshall Lyon; Aneesh K Mehta; Gokul Kumar; Justine R Smith; Markus H Kainulainen; Shannon Whitmer; Ute Ströher; Timothy M Uyeki; Bruce S Ribner; Steven Yeh Journal: N Engl J Med Date: 2015-05-07 Impact factor: 91.245
Authors: Amy James Loftis; Saturday Quellie; Kelly Chason; Emmanuel Sumo; Mason Toukolon; Yonnie Otieno; Heinzfried Ellerbrok; Marcia M Hobbs; David Hoover; Karine Dube; David A Wohl; William A Fischer Journal: J Infect Dis Date: 2017-02-01 Impact factor: 5.226
Authors: William A Fischer; Jerry Brown; David Alain Wohl; Amy James Loftis; Sam Tozay; Edwina Reeves; Korto Pewu; Galapaki Gorvego; Saturday Quellie; Coleen K Cunningham; Carson Merenbloom; Sonia Napravnik; Karine Dube; David Adjasoo; Erin Jones; Korlia Bonarwolo; David Hoover Journal: Open Forum Infect Dis Date: 2017-07-22 Impact factor: 3.835
Authors: A de St Maurice; E Ervin; R Orone; M Choi; E K Dokubo; P E Rollin; S T Nichol; D Williams; J Brown; R Sacra; J Fankhauser; B Knust Journal: Open Forum Infect Dis Date: 2018-09-21 Impact factor: 3.835
Authors: Michael Jacobs; Alison Rodger; David J Bell; Sanjay Bhagani; Ian Cropley; Ana Filipe; Robert J Gifford; Susan Hopkins; Joseph Hughes; Farrah Jabeen; Ingolfur Johannessen; Drosos Karageorgopoulos; Angie Lackenby; Rebecca Lester; Rebecca S N Liu; Alisdair MacConnachie; Tabitha Mahungu; Daniel Martin; Neal Marshall; Stephen Mepham; Richard Orton; Massimo Palmarini; Monika Patel; Colin Perry; S Erica Peters; Duncan Porter; David Ritchie; Neil D Ritchie; R Andrew Seaton; Vattipally B Sreenu; Kate Templeton; Simon Warren; Gavin S Wilkie; Maria Zambon; Robin Gopal; Emma C Thomson Journal: Lancet Date: 2016-05-18 Impact factor: 79.321
Authors: Himiede W Wilson; Maame Amo-Addae; Ernest Kenu; Olayinka Stephen Ilesanmi; Donne K Ameme; Samuel O Sackey Journal: Biomed Res Int Date: 2018-06-28 Impact factor: 3.411
Authors: Nell G Bond; Donald S Grant; Sarah T Himmelfarb; Emily J Engel; Foday Al-Hasan; Michael Gbakie; Fatima Kamara; Lansana Kanneh; Ibrahim Mustapha; Adaora Okoli; William Fischer; David Wohl; Robert F Garry; Robert Samuels; Jeffrey G Shaffer; John S Schieffelin Journal: Clin Infect Dis Date: 2021-09-15 Impact factor: 20.999
Authors: Dominic Paquin-Proulx; Bronwyn M Gunn; Aljawharah Alrubayyi; Danielle V Clark; Matthew Creegan; Dohoon Kim; Hannah Kibuuka; Monica Millard; Salim Wakabi; Leigh Anne Eller; Nelson L Michael; Randal J Schoepp; Matthew J Hepburn; Lisa E Hensley; Merlin L Robb; Galit Alter; Michael A Eller Journal: Front Immunol Date: 2021-05-20 Impact factor: 7.561
Authors: Robert J Watson; Julia Tree; Susan A Fotheringham; Yper Hall; Xiaofeng Dong; Kimberley Steeds; Jade Gouriet; Francisco J Salguero; Christopher Burton; James Pitman; Linda Easterbrook; Kevin S Richards; Jane Burton; Kevin Bewley; Christine Bruce; Julian A Hiscox; Miles W Carroll; Simon G P Funnell Journal: J Virol Date: 2021-09-29 Impact factor: 5.103